Knowledge and attitudes of permanent chemotherapy-induced alopecia among health care providers.

Authors

null

Jenna Rose Stoehr

Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL

Jenna Rose Stoehr, Cory Kosche, Jennifer N. Choi

Organizations

Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL

Research Funding

No funding received
None

Background: Reports of permanent chemotherapy-induced alopecia (PCIA) are increasing in the field of oncodermatology, but there is a dearth of information regarding how it is recognized and managed by health care providers (HCPs) across different medical specialties. Methods: An electronic survey was distributed to HCPs (resident physicians, attending physicians, and nurse practitioners) in the departments of dermatology, oncology, and general internal medicine (GIM) within one Midwestern hospital system. Results: Of the 62 participants (response rate: 13%), there were 19 from dermatology, 20 from oncology, and 23 from GIM. Responses were analyzed with descriptive statistics, and chi-square and ANOVA tests. There was a significant difference in the number of subjects that had heard of PCIA prior to starting the survey (Derm: 79%, Onc: 30%, GIM: 22%, p<0.05). A larger percentage of dermatology and oncology HCPs knew the correct definition of the condition (alopecia persisting >6 months) than GIM (42% and 45% vs. 17%) and significantly more had encountered patients with the condition (47% and 45% vs. 17%). More providers in dermatology and GIM knew how to diagnose PCIA compared to oncology (84% and 83% vs. 70%). Dermatology HCPs were the only participants who had attempted to treat patients with PCIA. Most providers across the three specialties believed that patients would accept PCIA treatment that was topical, oral, injectable, and required frequent administration or monitoring, but not treatment that was expensive or high risk. A majority of HCPs surveyed (94%) agreed that the diagnosis of PCIA is important. However, there was a significant difference in the confidence of HCPs in diagnosing and managing PCIA. A minority of dermatology providers (2/19) specified that they would refer to an alopecia or oncodermatology specialist, while the majority of oncology and GIM providers would refer to dermatology. Conclusions: The results of this survey identify knowledge gaps about PCIA amongst health care providers. Therefore, education and multidisciplinary engagement should be pursued in order to improve awareness, diagnosis, referral, and management of PCIA as part of survivorship care.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2019 Supportive Care in Oncology Symposium

Session Type

Poster Session

Session Title

Poster Session B

Track

Mental Health and Psychological Well-being,Psychosocial and Spiritual/Cultural Assessment and Management,Models of Care,Patient Reported Outcomes and Patient Experience,Prevention, Assessment, and Management of Disease and Treatment-related Symptoms,Prognostication ,Survivorship and Late Effects of Cancer

Sub Track

Survivorship and Late Effects of Cancer

Citation

J Clin Oncol 37, 2019 (suppl 31; abstr 142)

DOI

10.1200/JCO.2019.37.31_suppl.142

Abstract #

142

Poster Bd #

F4

Abstract Disclosures

Similar Abstracts

First Author: Eric Hess

Abstract

2023 ASCO Annual Meeting

National Coalition for Cancer Survivorship State of Survivorship Survey.

First Author: Shelley Fuld Nasso

First Author: Lisa Mikesell

First Author: Michelle Payan